Limits...
Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.

Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y, Le H - PLoS ONE (2014)

Bottom Line: Altered expression of miRNA expression contributes to human carcinogenesis.Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC.The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Joint Immunogenomics Laboratory, Zhoushan Hospital, Zhoushan, Zhejiang, China.

ABSTRACT

Background: Altered expression of miRNA expression contributes to human carcinogenesis. This study was designed to detect aberrant miRNA expressions as a potential biomarker for early detection and prognosis prediction of non-small cell lung cancer (NSCLC).

Methods: miRNA array was used to profile differentially expressed miRNAs and Taqman-based quantitative RT-PCR assays were used to analyze levels of miR-29c, miR-93, and miR-429 expression in NSCLC tissue samples, corresponding normal tissue samples, and serum samples from 70 NSCLC patients as well as in serum samples from 48 healthy controls.

Results: Levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues, while serum levels of miR-29c were also upregulated, but levels of serum miR-429 were decreased in NSCLC. Moreover, the levels of miR-429 expression in NSCLC tissues were associated with those in serum samples. Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC. In addition, serum levels of miR-429 were associated with poor overall survival of NSCLC patients. Both univariate and multivariate analyses showed that serum miR-429 level was an independent prognostic predictor for NSCLC.

Conclusions: The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival curves for NSCLC patients according to serum level of miR-429.P-value for survival of patients with high and low levels of miRNA expression was calculated using the log-rank test. *P<0.05 between groups.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3921142&req=5

pone-0087780-g003: Kaplan-Meier survival curves for NSCLC patients according to serum level of miR-429.P-value for survival of patients with high and low levels of miRNA expression was calculated using the log-rank test. *P<0.05 between groups.

Mentions: Because the expression of the three tested miRNAs was altered in NSCLC tissue and serum samples, we further evaluated whether detection of their levels could predict prognosis in NSCLC patients. We found that the serum level of miR-429 expression was associated with the overall survival of NSCLC patients (P = 0.0030 using a Log-rank test, Figure 3). However, expression of miR-29c, miR-93, and miR-429 in NSCLC tissues and serum levels of miR-29c and miR-93 were not associated with the overall survival of NSCLC patients. The univariate Cox hazard regression analysis demonstrated that serum levels of miR-429 were a significant prognostic indicator of NSCLC (adjusted hazard ratio = 6.458, 95% CI: 1.409–29.593, P = 0.016). The multivariate Cox proportional hazard regression analysis showed that serum levels of miR-429 were an independent prognostic predictor for NSCLC patients (hazard ratio = 12.875, 95% CI: 2.295–72.230, P = 0.004, Table 3).


Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.

Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, Liu X, Zhang Y, Le H - PLoS ONE (2014)

Kaplan-Meier survival curves for NSCLC patients according to serum level of miR-429.P-value for survival of patients with high and low levels of miRNA expression was calculated using the log-rank test. *P<0.05 between groups.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3921142&req=5

pone-0087780-g003: Kaplan-Meier survival curves for NSCLC patients according to serum level of miR-429.P-value for survival of patients with high and low levels of miRNA expression was calculated using the log-rank test. *P<0.05 between groups.
Mentions: Because the expression of the three tested miRNAs was altered in NSCLC tissue and serum samples, we further evaluated whether detection of their levels could predict prognosis in NSCLC patients. We found that the serum level of miR-429 expression was associated with the overall survival of NSCLC patients (P = 0.0030 using a Log-rank test, Figure 3). However, expression of miR-29c, miR-93, and miR-429 in NSCLC tissues and serum levels of miR-29c and miR-93 were not associated with the overall survival of NSCLC patients. The univariate Cox hazard regression analysis demonstrated that serum levels of miR-429 were a significant prognostic indicator of NSCLC (adjusted hazard ratio = 6.458, 95% CI: 1.409–29.593, P = 0.016). The multivariate Cox proportional hazard regression analysis showed that serum levels of miR-429 were an independent prognostic predictor for NSCLC patients (hazard ratio = 12.875, 95% CI: 2.295–72.230, P = 0.004, Table 3).

Bottom Line: Altered expression of miRNA expression contributes to human carcinogenesis.Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC.The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Joint Immunogenomics Laboratory, Zhoushan Hospital, Zhoushan, Zhejiang, China.

ABSTRACT

Background: Altered expression of miRNA expression contributes to human carcinogenesis. This study was designed to detect aberrant miRNA expressions as a potential biomarker for early detection and prognosis prediction of non-small cell lung cancer (NSCLC).

Methods: miRNA array was used to profile differentially expressed miRNAs and Taqman-based quantitative RT-PCR assays were used to analyze levels of miR-29c, miR-93, and miR-429 expression in NSCLC tissue samples, corresponding normal tissue samples, and serum samples from 70 NSCLC patients as well as in serum samples from 48 healthy controls.

Results: Levels of miR-29c and miR-93 expression were upregulated in NSCLC tissues, while serum levels of miR-29c were also upregulated, but levels of serum miR-429 were decreased in NSCLC. Moreover, the levels of miR-429 expression in NSCLC tissues were associated with those in serum samples. Receiver operating characteristic (ROC) curve analysis showed that at the optimal cut-off point, the areas under the ROC curve for serum levels of miR-29c and miR-429 were 0.723 and 0.727, respectively, levels which are higher than that of carcinoma embryonic antigen (0.534) in diagnosis of stage I NSCLC. In addition, serum levels of miR-429 were associated with poor overall survival of NSCLC patients. Both univariate and multivariate analyses showed that serum miR-429 level was an independent prognostic predictor for NSCLC.

Conclusions: The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel, non-invasive biomarker for early stage NSCLC.

Show MeSH
Related in: MedlinePlus